Connect with us
European Gaming Congress 2024

Latest News

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Published

on

  • Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas.
  • Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD, and double-digit royalties on annual sales
  • Additionally, Takeda will purchase a minority interest in Ascentage Pharma

ROCKVILLE, Md. and SUZHOU, China, June 14, 2024 /PRNewswire/ — Ascentage Pharma (6855 HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib in all territories outside of among others, mainland China, Hong Kong, Macau, Taiwan, China.

Despite the impact TKIs have had in the treatment of patients with CML, there remains a significant unmet need for patients whose disease is resistant to these therapies or who develop hard-to-treat mutations following these treatments.

Under the terms of this option agreement, Ascentage Pharma is set to receive 100 million USD from Takeda to acquire the option to license olverembatinib. Ascentage will also be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD. Additionally, Ascentage Pharma is expected to receive a minority equity investment from Takeda.

As part of the agreement, Ascentage Pharma will continue to be solely responsible for all clinical development of olverembatinib before the potential exercise of the option to license olverembatinib. Olverembatinib is currently approved and marketed in China for the treatment of adult patients with TKI-resistant chronic-phase CML (CP-CML) or accelerated-phase CML (AP-CML) harboring the T315I mutation, and in adult patients with CP-CML resistant to and/or intolerant of first-and second-generation TKIs.

“We are thrilled to enter into this agreement with Takeda, which would allow us to leverage the global commercial expertise of an organization with a proven track record and global oncology footprint to potentially broaden the impact olverembatinib could have on patients in need around the world,” said Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma. “Olverembatinib has already had a significant impact for patients with CML in China. We are excited to further the development of olverembatinib in our ongoing global registrational Phase 3 studies.”

“Throughout our history in oncology, Takeda has demonstrated a strong track record of working with companies that share our vision of bringing medicines to patients around the world with the highest unmet needs,” said Teresa Bitetti, president of Takeda’s Global Oncology Business Unit. “Through this agreement with Ascentage Pharma, we believe there is great potential to continue to advance this mission. We are highly encouraged by the promising results olverembatinib has shown in the clinic to date, and excited to have the opportunity to further develop and deliver it to patients with chronic myeloid leukemia and other hematological cancers.”

Advertisement
Stake.com

About Olverembatinib

Olverembatinib, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug has been included in the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates.

Investors Contacts:[email protected]
Media Contacts:PR@ ascentage.com

Advertisement
Stake.com

Forward-Looking Statements

The forward-looking statements in this article relate only to the events or information as of the date on which the statements are made. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Logo – https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/ascentage-pharma-signs-option-agreement-with-takeda-to-enter-into-exclusive-global-license-for-olverembatinib-a-third-generation-bcr-abl-tyrosine-kinase-inhibitor-tki-302173072.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Setgaji Launches in Malaysia, Leading Global Financial Wellness

Published

on

KUALA LUMPUR, Malaysia, June 18, 2024 /PRNewswire/ — Prepare for a paradigm shift in financial empowerment with Setgaji Sdn. Bhd.’s groundbreaking platform, Setgaji. This innovative solution redefines how financial wellness is managed, setting a new standard for accessibility and empowerment.

Setgaji leads the charge towards a brighter future by revolutionising the timing and accessibility of salary withdrawals. This platform not only simplifies processes but also enhances employee motivation and satisfaction, creating rewarding work experiences.

More than just a tool, Setgaji is a movement committed to empowering individuals and transforming workplace practices. By providing early access to earned wages, Setgaji enables healthier financial habits and eliminates the need for high-interest loans for Malaysians in the workforce.

Unique to Setgaji is its pioneering feature as Malaysia’s earned wage access platform that is completely free for both employees and employers. This transparency ensures no hidden costs for employees while employers benefit from earning air miles with each transaction.

“We are excited to introduce Setgaji to the global stage, where financial wellness is our ultimate goal for the workforce,” said Mr. Micheal Ngu Kiet Ting, COO of Setgaji Sdn. Bhd. “Our platform signifies a revolutionary approach to financial management, offering employees autonomy in today’s fast-paced world.”

Advertisement
Stake.com

The pathway for a transformative journey towards financial wellness is here. Discover how Setgaji reshapes the landscape of financial practices at www.setgaji.com

About Setgaji Sdn. Bhd.

Setgaji Sdn. Bhd. is a dynamic financial solutions provider, specializing in early wage access services for employees. Since 2024, we have established ourselves as a trusted authority in pioneering financial solutions, addressing cash flow challenges and promoting employee financial well-being. Our mission is to reshape financial practices and foster sustainable financial habits among employees through innovative solutions tailored to modern organizational needs.

Photo – https://mma.prnewswire.com/media/2441386/Press_Release_Image__1.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/setgaji-launches-in-malaysia-leading-global-financial-wellness-302175415.html

Advertisement
Stake.com
Continue Reading

Latest News

Stax Opens New Central London Office Amidst Rapid U.K. Expansion

Published

on

NEW YORK, June 18, 2024 /PRNewswire/ — Stax LLC, a global strategy consulting firm specializing in commercial due diligence, value creation, and exit planning for private equity firms, PE-backed companies, hedge funds, and investment banks, today announced the opening of a new office in Central London. This expansion follows the January hiring of Phil Dunne as managing director to lead the firm’s U.K. and EMEA practice and strategic growth efforts. Aiming to double its headcount by 2025, Stax quickly outgrew its previous space in less than a year and sought new premises to accommodate its rapid expansion in the U.K. market. Stax’s substantial growth with U.K. and European private equity clients, coupled with its team expansion, underscores the enduring appeal of the U.K. mid-market—particularly in the M&A landscape and private equity ecosystem.

“It’s exciting to witness Stax expanding once again in London. As I lead our U.K. and EMEA growth strategy, we are keenly focused on strengthening our brand in the local market,” stated Phil Dunne, U.K. Managing Director. “We have recently achieved significant accolades, such as being named a finalist in the 2024 Real Deals Private Equity Awards for Commercial Due Diligence Provider of the Year. Additionally, we just won the U.S. SME Growth and Investment in the U.K. award at the BritishAmerican Business Transatlantic Growth Awards.”

Dunne elaborated, “Another key objective is team expansion, with the goal of doubling our headcount by 2025. As Stax broadens its sector expertise, we are actively recruiting at all levels with a special emphasis on strategic senior roles, particularly in healthcare and consumer verticals. This will enable us in London to provide our clients with a comprehensive portfolio of specialized experts spanning across technology, industrials, business services, healthcare, consumer and retail, and information services.”

“This year, as we celebrate the 30th anniversary of Stax, we’re excited to be closer to our London-based clients to better serve their needs. We continue to deliver transaction advisory services to our extensive roster of U.S.-based clients who are rapidly entering into the U.K. market, as well as our U.K. and EMEA-based clients expanding into the U.S. market. By supporting both sides of this dynamic ecosystem, Stax is experiencing significant growth,” shared Paul Edwards, Global Practice Leader. “We are committed to our U.K. growth strategy and leveraging it to drive our expansion across Europe, fueled by substantial growth in our European private equity engagements from clients who value our unique, data-driven advisory offerings.”

As Stax strives to deliver the highest level of service to our clients, the company is also dedicated to strengthening its European team and providing employees with expanded resources and opportunities for professional growth and development. Stax is hiring across levels, with a particular focus on senior leaders with healthcare and consumer expertise. Those interested in joining a dynamic organization and a growing U.K. team are encouraged to apply now.

Advertisement
Stake.com

About Stax LLC 

Stax LLC is a global management consulting firm serving corporate and private equity clients across a broad range of industries including software/technology, healthcare, business services, industrial, consumer/retail, and the events ecosystem. The firm partners with clients to provide data-driven, actionable insights designed to drive growth, enhance profits, increase value, and make better investment decisions. Please visit www.stax.com and follow Stax on LinkedIn, Instagram, Threads, and Facebook. 

Logo – https://mma.prnewswire.com/media/2428526/Stax_logo_w_tagline_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/stax-opens-new-central-london-office-amidst-rapid-uk-expansion-302173350.html

Continue Reading

Latest News

Millionaires on the Move: Where are the World’s Wealthy Migrating to and from in 2024?

Published

on

LONDON, June 18, 2024 /PRNewswire/ — The UK is expected to see an unprecedented net loss of 9,500 millionaires in 2024 — second only to China worldwide, and more than double the 4,200 who left the country last year, which was itself record-breaking following the exodus of 1,600 HNWIs in 2022. For the third year running, the UAE looks set to take first place as the world’s leading wealth magnet, with a record-breaking 6,700 moneyed migrants expected to make the Emirates home by the end of the year, boosted by large inflows from the UK and Europe.

The Henley Private Wealth Migration Report 2024, released today by international investment migration advisory firm Henley & Partners, features the most significant projected millionaire migrant inflows and outflows globally as well as the W15 ranking of the world’s top 15 countries for millionaires, centi-millionaires and billionaires. 

China is again on track to be the biggest millionaire loser globally, with an anticipated net exit of 15,200 HNWIs this year (compared to 13,800 in 2023) whereas India has stemmed its wealth exodus, dropping down to 3rd place after the UK with just 4,300 millionaires projected to leave the country in 2024 (compared to 5,100 last year). South Korea’s HNWI flight is expected to rise with a forecast loss of 1,200 millionaires (compared to 800 in 2023) while the tsunami of millionaires that fled Russia following the outbreak of the Ukraine war appears to be abating with only 1,000 projected to relocate this year (compared to 8,500 in 2022 and 2,800 in 2023).

Dominic Volek, Group Head of Private Clients at Henley & Partners, says 2024 is shaping up to be a watershed moment in the global migration of wealth: “An unprecedented 128,000 millionaires are expected to relocate worldwide this year, eclipsing the previous record of 120,000 set in 2023. As the world grapples with a perfect storm of geopolitical tensions, economic uncertainty, and social upheaval, millionaires are voting with their feet in record numbers.”

UAE remains world’s leading millionaire magnet

Advertisement
Stake.com

With its zero income tax, golden visas, luxury lifestyle, and strategic location, the UAE has entrenched itself as the world’s number one destination for migrating millionaires and is poised to attract nearly twice as many millionaires as its nearest rival, the US, which is projected to benefit from a net inflow of 3,800 millionaires in 2024.

Singapore takes 3rd prize again this year with net inflows of 3,500, while the perennially popular destinations for migrating millionaires, Canada and Australia, follow in 4th and 5th places with net inflows of 3,200 and 2,500, respectively. European favorites Italy (+2,200), Switzerland (+1,500), Greece (+1,200) and Portugal (+800) all make it into this year’s Top 10 for net millionaire inflows along with Japan, which is on course to welcome 400 wealthy migrants, boosted in part by an accelerating trend of Chinese HNWIs moving to Tokyo that started post-Covid.

The other big millionaire losers in 2024

Besides China, the UK, India, South Korea, and Russia, the remaining places in the Top 10 millionaire outflow ranking are taken up by Brazil where a millionaire drain of 800 is projected this year, followed by South Africa (-600), Taiwan (-400), and Vietnam and Nigeria, which are both set to see 300 millionaires take flight.

But as Dr. Hannah White OBE, Director and CEO of the Institute for Government in London points out, HNWIs are leaving these other countries for quite different reasons from the UK: “Both China and India are seeing high net outflows because of the success of their sizeable economies in generating new millionaires, although slowing wealth growth in China in recent years could mean sustained losses become more damaging over time. As do those from many other developing nations, including notably Brazil, Vietnam, South Africa, and Nigeria, Indian millionaires often depart the sub-continent in search of a better lifestyle, safer and cleaner environments, and access to more premium health and education services. Elsewhere, regional threats and uncertainty over the security stance of America following a potential Trump victory in the 2024 US presidential election in November mean that South Korea and Taiwan are continuing to see net outflows of HNWIs.”

Advertisement
Stake.com

The surge in millionaire migration is fueling a corresponding boom in the investment migration sector. Henley & Partners has received record levels of enquiries about residence and citizenship by investment programs over the past 12 months from nearly 200 different countries. The top two nationalities currently driving demand are Americans and Indians, with Brits, Filipinos, and South Africans remaining in the Top 10 as they have done for the last five years.

Read the full press release.

View original content:https://www.prnewswire.co.uk/news-releases/millionaires-on-the-move-where-are-the-worlds-wealthy-migrating-to-and-from-in-2024-302172211.html

Continue Reading

Trending